CCA
LLY icon

Cravens & Co Advisors’s Eli Lilly LLY Stock Holding History

Cravens & Co Advisors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
1,236
-271
-18% -$277K 1% 22
2026
Q1 		$1.39M Buy
1,507
+3
+0.2% +$3.04K 0.9% 26
2025
Q4 		$1.62M Sell
1,504
-15
-1% -$14.3K 1.06% 24
2025
Q3 		$1.16M Sell
1,519
-15
-1% -$11.2K 0.79% 30
2025
Q2 		$1.2M Buy
+1,534
New +$1.19M 0.89% 27

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cravens & Co Advisors's LLY Position: Q2 2026 in Review

Cravens & Co Advisors reduced its Eli Lilly (LLY) stake by 18% in Q2 2026, selling an estimated $277K and leaving 1,236 shares worth $1.48M. The position accounts for 1% of the portfolio, ranked #22.

Cravens & Co Advisors first reported a position in LLY in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.62M in Q4 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cravens & Co Advisors held 1,236 shares of Eli Lilly worth $1.48M as of Q2 2026.
  • Cravens & Co Advisors sold 271 Eli Lilly shares in Q2 2026, an estimated $277K.
  • Eli Lilly made up 1% of Cravens & Co Advisors's portfolio in Q2 2026, its #22 holding.
  • Cravens & Co Advisors first reported a position in Eli Lilly in Q2 2025 and has held it in 5 quarters since.
  • Cravens & Co Advisors's Eli Lilly position peaked at $1.62M in Q4 2025.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.